SCHEMBL3258489

SCHEMBL3258489

Cc1ccc(-c2nn(C)cc2-c2ccnc(Cl)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.53
MAPK9 P45984 2/20 0.53
CSNK1A1 P48729 2/20 0.53
EGFR P00533 1/20 0.53
FRK P42685 1/20 0.53
CSNK1D P48730 12/20 0.46
CSNK1E P49674 8/20 0.46
MAPK14 Q16539 5/20 0.46
MAPK11 Q15759 4/20 0.46
MAPK13 O15264 2/20 0.46
MAPK12 P53778 2/20 0.46
KCNH2 Q12809 2/20 0.42
BRAF P15056 7/20 0.40
NUAK1 O60285 1/20 0.40
ROCK2 O75116 1/20 0.40
LCK P06239 1/20 0.40
MAPK8 P45983 1/20 0.40
GSK3B P49841 1/20 0.40
MAP2K1 Q02750 1/20 0.40
MINK1 Q8N4C8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5094894 0.82 MAP4K4 (0.50) MAP4K4MAPK9CSNK1A1EGFRFRK
SCHEMBL19556261 0.81 ALDH1A1 (0.46) MAP4K4MAPK9CSNK1A1EGFRFRK
SCHEMBL444442 0.77 KMT2A (0.56) MAP4K4
SCHEMBL8240895 0.77 MAP4K4 (0.39) MAP4K4MAPK9CSNK1A1EGFRFRK
SCHEMBL3247852 0.76 PIK3CA (0.44) MAP4K4MAPK9CSNK1A1EGFRFRK
SCHEMBL22789740 0.76 MAP4K4 (0.64) MAP4K4MAPK9CSNK1A1EGFRFRK
SCHEMBL3247462 0.75 MEN1 (0.41) MAPK14AURKBMAPK1
SCHEMBL3258114 0.72 ACVR1 (0.62) EGFRGSK3B
SCHEMBL16105320 0.71 MAPK9 (0.58) MAP4K4MAPK9CSNK1A1EGFRFRK
SCHEMBL30603649 0.70 KDM4E (0.39) MAP4K4MAPK9CSNK1A1EGFRFRK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521749-B8 PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES NOVARTIS AG (CH) 2010-12-22 EP disclosed
EP-1521749-B1 PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES NOVARTIS AG (CH) 2010-05-19 EP disclosed
US-7691855-B2 Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives NOVARTIS AG (CH) 2010-04-06 US disclosed
CN-1330643-C Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives NOVARTIS AG (CH) 2007-08-08 CN disclosed
US-20060106027-A1 Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives FURET PASCAL 2006-05-18 US disclosed
CN-1668610-A Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives NOVARTIS AG (CH) 2005-09-14 CN disclosed
EP-1521749-A1 PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES Novartis AG (CH) 2005-04-13 EP disclosed
WO-2004005282-A1 PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES NOVARTIS AG (CH) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106027-A1 Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives MKI67, CCNI, PAH MAP4K4 546/4885MAPK9 1591/4885CSNK1A1 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.